Internal Medicine, Medical Oncology · New Haven, CT
NPI
1104814888
Since 2005
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
800 Howard Ave, Yale Physicians Building
New Haven, CT, 06519
Phone (203) 785-2140
Groups this clinician bills Medicare through
Medicare paid, 2024
$44K
575 services
Medicare patients, 2024
136
Average age 73
Drug cost, 2024
$933K
648 prescriptions
Company payments, 2025
$29K
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Francine M Foss was code 99214 (office e&m - established), 249 times for 90 patients. In total Francine M Foss billed 575 services in 15 codes, and Medicare paid $44K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-01-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 249 | 90 | $75.56 | $19K |
| 99232 Hospital E&M - Subsequent | Facility | 129 | 24 | $64.22 | $8,285 |
| 99214 Office E&M - Established | Office | 50 | 28 | $100.05 | $5,002 |
| 99443 Telephone Services | Facility | 28 | 16 | $72.49 | $2,030 |
| 99213 Office E&M - Established | Facility | 15 | 14 | $51.69 | $775 |
| 99239 Hospital Discharge Management | Facility | 12 | 11 | $93.05 | $1,117 |
By year: 2022 $55K for 693 services; 2023 $44K for 540 services; 2024 $44K for 575 services.
Medicare prescription drug claims, 2024
In 2024, the drug Francine M Foss prescribed most often to Medicare patients was Acyclovir, with 65 prescriptions and refills. In total Francine M Foss wrote 648 Medicare prescriptions that cost $933K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 65 | 103 | 25 | $869 |
| Prednisone Generic | 41 | 69 | 22 | $303 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 36 | 43 | 14 | $347 |
| Bexarotene Generic | 28 | 28 | Under 11 | $83K |
| Potassium Chloride Generic | 27 | 29 | Under 11 | $184 |
| Levothyroxine Sodium Generic | 25 | 61 | Under 11 | $371 |
| Triamcinolone Acetonide Generic | 23 | 27 | 12 | $183 |
| Methotrexate Methotrexate Sodium | 16 | 25 | Under 11 | $80.24 |
| Pantoprazole Sodium Generic | 16 | 30 | Under 11 | $105 |
| Ursodiol Generic | 14 | 14 | Under 11 | $368 |
| Jakafi Ruxolitinib Phosphate | 13 | 13 | Under 11 | $225K |
| Breo Ellipta Fluticasone/Vilanterol | 13 | 13 | Under 11 | $4,552 |
| Rosuvastatin Calcium Generic | 13 | 30 | Under 11 | $83.65 |
| Hydroxyzine Hcl Generic | 13 | 17 | Under 11 | $113 |
| Amlodipine Besylate Generic | 12 | 14 | Under 11 | $75.63 |
Brand drugs: 109 claims; generic drugs: 539 claims; opioid claims: 11.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Francine M Foss $29K ($25K in general payments such as food, travel and fees and $4,350 for research) from 8 companies. The largest payer was Kyowa Kirin, Inc. with $17K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.